References
- Dhanwal DK, Cooper C, Dennison EM. Geographic variation in osteoporotic hip fracture incidence: the growing importance of Asian influences in coming decades. J Osteoporos. 2010;2010:757102. doi:10.4061/2010/75710220981334
- Cheung EYN, Tan KCB, Cheung CL, Kung AWC. Osteoporosis in East Asia: current issues in assessment and management. Osteoporos Sarcopenia. 2016;2(3):118–133. doi:10.1016/j.afos.2016.07.00130775478
- Mithal A, Ebeling P. Asia pacific regional audit. Epidemiology, costs & burden of osteoporosis in 2013; 2013 Available from: https://www.iofbonehealth.org/sites/default/files/media/PDFs/Regional%20Audits/2013-Asia_Pacific_Audit_0_0.pdf. Accessed 130, 2019.
- Hwang JS, Chan DC, Chen JF, et al. Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary. J Bone Miner Metab. 2014;32(1):10–16. doi:10.1007/s00774-013-0495-024068612
- Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726–1733. doi:10.1007/s00198-006-0172-416983459
- Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2(6):285–289. doi:10.1007/BF16231841421796
- Lau EM, Lee JK, Suriwongpaisal P, et al. The incidence of hip fracture in four Asian countries: the Asian Osteoporosis Study (AOS). Osteoporos Int. 2001;12(3):239–243. doi:10.1007/s00198017013511315243
- Lau EMC, Sambrook P, Seeman E, Leong KH, Leung PC, Delmas P. Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia. APLAR J Rheumatol. 2006;9(1):24–36. doi:10.1111/j.1479-8077.2006.00161.x
- Chen CH, Elsalmawy AH, Ish-Shalom S, et al. Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS). Curr Med Res Opin. 2019;35(6):1041–1049. doi:10.1080/03007995.2018.155257630474449
- Yu F, Xia W. The epidemiology of osteoporosis, associated fragility fractures, and management gap in China. Arch Osteoporos. 2019;14(1):32. doi:10.1007/s11657-018-0549-y30848398
- Forteo (teriparatide) [rDNA origin] injection) for subcutaneous use [US prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2012 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021318s036lbl.pdf. Accessed 129, 2019.
- European Medicines Agency. Forsteo summary of product characteristics; 2013 Available from: https://www.ema.europa.eu/en/documents/product-information/forsteo-epar-product-information_en.pdf. Accessed 129, 2019.
- Forsteo (teriparatide) [rDNA origin] injection) for subcutaneous use [China prescribing information]. 2019.
- Forteo (teriparatide) [rDNA origin] injection) for subcutaneous use [Taiwan prescribing information]. 2012 Available from: https://www.fda.gov.tw/MLMS/ShowFile.aspx?LicId=10000787&Seq=052&Type=9. Accessed 78, 2019.
- Forteo (teriparatide) [rDNA origin] injection) for subcutaneous use [Hong Kong prescribing information]. 2014 Available from: https://www.mims.com/hongkong/drug/info/forteo. Accessed 711, 2019.
- Forsteo (teriparatide) [rDNA origin] injection) for subcutaneous use [South Korea prescribing information]. 2015 Available from: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200209623. Accessed 711, 2019.
- Cheng XG, Yang DZ, Zhou Q, et al. Age-related bone mineral density, bone loss rate, prevalence of osteoporosis, and reference database of women at multiple centers in China. J Clin Densitom. 2007;10(3):276–284. doi:10.1016/j.jocd.2007.05.00417604665
- Cui LH, Choi JS, Shin MH, et al. Prevalence of osteoporosis and reference data for lumbar spine and hip bone mineral density in a Korean population. J Bone Miner Metab. 2008;26(6):609–617. doi:10.1007/s00774-007-0847-818979161
- Iki M, Kagamimori S, Kagawa Y, Matsuzaki T, Yoneshima H, Marumo F. Bone mineral density of the spine, hip and distal forearm in representative samples of the Japanese female population: Japanese Population-Based Osteoporosis (JPOS) Study. Osteoporos Int. 2001;12:529–537. doi:10.1007/s00198017007311527049
- Lynn HS, Lau EM, Au B, Leung PC. Bone mineral density reference norms for Hong Kong Chinese. Osteoporos Int. 2005;16(12):1663–1668. doi:10.1007/s00198-005-1899-z16027958
- Yeh LR, Chen CK, Lai PH. Normal bone mineral density in anteroposterior, lateral spine and hip of Chinese men in Taiwan: effect of age change, body weight and height. J Chin Med Assoc. 2004;67(6):287–295.15366406
- National Health Insurance Administration (Taiwan). Chapter 5. Hormones & drugs affecting hormonal mechanism; 2019 Available from: https://www.nhi.gov.tw/Content_List.aspx?n=E70D4F1BD029DC37&topn=3FC7D09599D25979. Accessed 514, 2019.
- Korea Insurance Charge Review Association. 2017 Available from: http://www.hicra.or.kr/sub_asp/04_data01.html?mode=read&read_no=1282&now_page=2&menu. Accessed 514, 2019.
- Orimo H, Nakamura T, Hosoi T, et al. Japanese 2011 guidelines for prevention and treatment of osteoporosis–executive summary. Arch Osteoporos. 2012;7:3–20. doi:10.1007/s11657-012-0109-923203733
- Rajzbaum G, Jakob F, Karras D, et al. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin. 2008;24(2):377–384. doi:10.1185/030079908X26108718154690
- Silverman S, Miller P, Sebba A, et al. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporos Int. 2013;24(8):2309–2317. doi:10.1007/s00198-013-2284-y23404615
- Soen S, Fujiwara S, Takayanagi R, et al. Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS). Curr Med Res Opin. 2017;33(11):2049–2056. doi:10.1080/03007995.2017.135482628699789
- The Osteoporosis Society of Hong Kong (OSHK) Task Group. 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. Hong Kong Med J. 2013;19(Suppl 2):S1–S140.
- Guidelines for primary osteoporosis diagnosis and management. Osteoporosis and bone mineral research society of the Chinese Medical Association; 2017 Available from: http://kns.cnki.net/kcms/detail/13.1222.R.20171027.1618.002.html. Accessed 514, 2019.
- Hagino H, Katagiri H, Okano T, Yamamoto K, Teshima R. Increasing incidence of hip fracture in Tottori Prefecture, Japan: trend from 1986 to 2001. Osteoporos Int. 2005;16(12):1963–1968. doi:10.1007/s00198-005-1974-516133645